CXCL4L1 hFc Chimera, Human
CXCL4L1 HFc Chimera, Human

The purity of CXCL4L1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

CXCL4L1 HFc Chimera, Human

CXCL4L1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CXCL4L1 hFc Chimera, Human

Platelet factor-4 (CXCL4/PF-4) was the first chemokine shown to inhibit angiogenesis. CXCL4L1/PF-4var, recently isolated from thrombin-stimulated platelets, differing from authentic CXCL4/PF-4 in three carboxy-terminally located amino acids, was found to be more potent than CXCL4/PF-4 in inhibiting angiogenesis and tumor growth. Both glycosaminoglycans (GAG) and CXCR3 are implicated in the activities of the PF-4 variants.
Z05208
¥55,963.00

Ask us a question
Product Introduction
Species Human
Protein Construction
CXCL4L1 (Phe31-Ser104)
Accession # P10720		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 35.01 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 43-48 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • CXCL4L1 HFc Chimera, Human
    • CXCL4L1 HFc Chimera, Human

    The purity of CXCL4L1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • CXCL4L1 HFc Chimera, Human
    • CXCL4L1 HFc Chimera, Human

    CXCL4L1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Platelet factor-4 (CXCL4/PF-4) was the first chemokine shown to inhibit angiogenesis. CXCL4L1/PF-4var, recently isolated from thrombin-stimulated platelets, differing from authentic CXCL4/PF-4 in three carboxy-terminally located amino acids, was found to be more potent than CXCL4/PF-4 in inhibiting angiogenesis and tumor growth. Both glycosaminoglycans (GAG) and CXCR3 are implicated in the activities of the PF-4 variants.
Synonyms Platelet factor 4 variant; CXCL4L1; PF4alt; PF4var1; CXCL4V1; PF4-ALT; PF4A; SCYB4V1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.